Testicular Radiomics To Predict Pathology At Time of Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumor

Venishetty, Nikit; Xi, Yin; Howard, Jeffrey; Ng, Yee S.; Wong, Daniel; Woldu, Solomon L.; Leon, Alberto Diaz de; Pedrosa, Iván; Margulis, Vitaly; Bagrodia, Aditya

doi:10.1016/j.clgc.2023.07.004

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address this limitation, we adopted a cross-validation methodology based on recurrent data partitioning, serving the dual purpose of guarding against overfitting and yielding precise model coefficient estimates [23]. Venishetty et al, using Pyradiomics in 45 patients undergoing PC-RPLND, failed to prove that radiomics analysis can predict pathology after retroperitoneal surgery [24]. In another retrospective study conducted at a single center [25], involving 77 patients with metastatic TGCT and a total of 102 lesions, the accuracy of radiomics to identify germ cell tumor vs teratoma vs fibrosis was 72 ± 2.2% (area under the curve [AUC], 0.74 ± 0.028); sensitivity was 56.2 ± 15.0%, and specificity was 81.9 ± 9.0%.…”

Section: Discussionmentioning

confidence: 99%

Radiomics Analyses to Predict Histopathology in Patients with Metastatic Testicular Germ Cell Tumors before Post-Chemotherapy Retroperitoneal Lymph Node Dissection

Scavuzzo,

Pasini,

Crescio

et al. 2023

J. Imaging

View full text Add to dashboard Cite

Background: The identification of histopathology in metastatic non-seminomatous testicular germ cell tumors (TGCT) before post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) holds significant potential to reduce treatment-related morbidity in young patients, addressing an important survivorship concern. Aim: To explore this possibility, we conducted a study investigating the role of computed tomography (CT) radiomics models that integrate clinical predictors, enabling personalized prediction of histopathology in metastatic non-seminomatous TGCT patients prior to PC-RPLND. In this retrospective study, we included a cohort of 122 patients. Methods: Using dedicated radiomics software, we segmented the targets and extracted quantitative features from the CT images. Subsequently, we employed feature selection techniques and developed radiomics-based machine learning models to predict histological subtypes. To ensure the robustness of our procedure, we implemented a 5-fold cross-validation approach. When evaluating the models’ performance, we measured metrics such as the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, precision, and F-score. Result: Our radiomics model based on the Support Vector Machine achieved an optimal average AUC of 0.945. Conclusions: The presented CT-based radiomics model can potentially serve as a non-invasive tool to predict histopathological outcomes, differentiating among fibrosis/necrosis, teratoma, and viable tumor in metastatic non-seminomatous TGCT before PC-RPLND. It has the potential to be considered a promising tool to mitigate the risk of over- or under-treatment in young patients, although multi-center validation is critical to confirm the clinical utility of the proposed radiomics workflow.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiomics Analyses to Predict Histopathology in Patients with Metastatic Testicular Germ Cell Tumors before Post-Chemotherapy Retroperitoneal Lymph Node Dissection

Scavuzzo,

Pasini,

Crescio

et al. 2023

J. Imaging

View full text Add to dashboard Cite

show abstract

“…The retroperitoneum is the initial site of lymph node metastasis in 70% to 80% of patients with TC [80]; the most common dissemination pathway is via lymphatic channels from the primary tumor to the retroperitoneal lymph nodes and subsequently to distant sites. The only exception is for choriocarcinoma, which has a propensity for hematogenous dissemination.…”

Section: Sexual Dysfunction After Rplndmentioning

confidence: 99%

Testicular Cancer Treatments and Sexuality: A Narrative Review

Raffo,

Di Naro,

Napolitano

et al. 2024

Medicina

View full text Add to dashboard Cite

The incidence of testicular cancer (TC) has been rapidly increasing over the past years. Diagnosis and early treatment have shown good oncological control, guaranteeing the patient different treatment approaches according to histology and tumor stage. Currently, physicians usually prioritize oncological outcomes over sexual outcomes and quality of life, considering as a first aim the overall survival of the patients; however, differently from other neoplasms, quality of life is still strongly affected among TC patients, and sexual outcomes are frequently compromised after each TC treatment. Several studies have suggested that each treatment approach may be associated with sexual dysfunctions, including erectile dysfunction, ejaculatory disorders, fertility issues, and hormonal changes. Since testicular cancer patients are more frequently young men, the subject of this work is substantial and should be analyzed in detail to help specialists in the management of this disease. The aim of the current narrative review is to generally describe every treatment for TC, including surgery, chemotherapy, radiotherapy, and retroperitoneal lymph node dissection, and to establish which sexual dysfunction may be specifically associated with each therapy.

show abstract